Overview

Safety and Efficacy of MP-214 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Risperidone